119 related articles for article (PubMed ID: 11023713)
1. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
Ambrosetti U; Dondè E; Piatti G; Cappellini MD
Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
[TBL] [Abstract][Full Text] [Related]
2. Long term audiological evaluation of beta-thalassemic patients.
Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
[TBL] [Abstract][Full Text] [Related]
3. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
[TBL] [Abstract][Full Text] [Related]
4. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
Karimi M; Asadi-Pooya AA; Khademi B; Asadi-Pooya K; Yarmohammadi H
Acta Haematol; 2002; 108(2):79-83. PubMed ID: 12187025
[TBL] [Abstract][Full Text] [Related]
6. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
Sacco M; Meleleo D; Tricarico N; Greco Miani A; Serra E; Parlatore L
Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
[TBL] [Abstract][Full Text] [Related]
8. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Chao YH; Wu KH; Lin CY; Tsai MH; Peng CT; Wu HP; Lin CD
Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
[TBL] [Abstract][Full Text] [Related]
9. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
[TBL] [Abstract][Full Text] [Related]
10. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
[TBL] [Abstract][Full Text] [Related]
11. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
[TBL] [Abstract][Full Text] [Related]
13. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of auditory function in homozygous beta-thalassemia].
Stura M; Arigliani R; Molinari AC; Tarantino V
Pediatr Med Chir; 1986; 8(5):703-5. PubMed ID: 3601700
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
[TBL] [Abstract][Full Text] [Related]
16. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
[TBL] [Abstract][Full Text] [Related]
17. Can deferoxamine be considered an ototoxic drug?
Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
[TBL] [Abstract][Full Text] [Related]
18. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ; Grady RW
Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
[TBL] [Abstract][Full Text] [Related]
19. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
